Stockscreener 앱 받기
26.21
1.31%
0.34
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze (MAZE) Trading: Ends Lower by 4.18% at $28.50 in the Latest Session; Price Context: the $27.07 to $29.93 Range Remains in FocusMESA MA - vinanet.vn
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine
Maze (MAZE) Price: Climbs 0.72% to $29.34 at the Close; Market Levels: Support at $27.87 and Resistance at $30.81 Frame the RangeVolume Oscillator - vinanet.vn
Trv Gp Iv LLC Invests $133.50 Billion in Maze Therapeutics, Inc. $MAZE - MarketBeat
Trv Gp V LLC Buys Shares of 950,800 Maze Therapeutics, Inc. $MAZE - MarketBeat
Alphabet Inc. Acquires New Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics Confirms MZE829 Data Readout for Late 2026 or Early 2027 - Minichart
Maze Therapeutics (MAZE) awards director 36,000 stock options - Stock Titan
Maze Therapeutics (MAZE) awards director 36K stock options - Stock Titan
Maze Therapeutics (NASDAQ: MAZE) director shows no stock or derivative holdings - Stock Titan
Maze Therapeutics (MAZE) director begins reporting with zero shares disclosed - Stock Titan
Maze Therapeutics names Paula Johnson, Sophie Kornowski to board of directors - Bitget
Maze Therapeutics (MAZE) Pulls Back 1.75% as Shares Consolidate Above Key SupportMomentum Factor - vinanet.vn
128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa
Maze Therapeutics president sells $445,620 in company stock - Investing.com
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock - MarketBeat
Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan - Stock Titan
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64 - Moomoo
HC Wainwright Has Positive Estimate for MAZE Q3 Earnings - MarketBeat
Maze Therapeutics (MAZE) Edges Higher to $27.66 as Shares Trade Within Established RangeETH Profile - vinanet.vn
Maze Therapeutics adds two directors to board By Investing.com - Investing.com Australia
Maze Therapeutics adds two directors to board - Investing.com
Maze Therapeutics Announces Appointments to Its Board of Directors - The Manila Times
Maze Therapeutics Appoints Paula Johnson and Sophie Kornowski to Board of Directors - Quiver Quantitative
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $48 to $110 - Moomoo
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics (NASDAQ:MAZE) Earns "Buy" Rating from BTIG Research - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
MAZE SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Maze Therapeutics (MAZE) reports $68.9M loss but ends Q2 with $494.9M in cash - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results - MarketBeat
Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
Maze Therapeutics Reports Q2 Net Loss Of $44.7 Million - Quiver Quantitative
Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses - TradingView
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times
Press Release: Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - Moomoo
Jason Coloma: The FTC Killed Our Sanofi Deal. Six Months Later, We Had a Better One. - finance.biggo.com
Maze Therapeutics (NASDAQ:MAZE) Trading Down 6.8%Should You Sell? - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook on a Biotech Stock with 119% Potential Upside - DirectorsTalk Interviews
MAZE Q1 2026 Earnings: Loss Narrower than Expected as No Revenue Is ReportedEarnings Weakness Phase - vinanet.vn
Maze Therapeutics (MAZE) Slides 2.16% to $27.21 as Biotech Volatility PersistsStock Buy Zone - Vinanet
Maze Therapeutics, Inc. (MAZE) CEO Coloma sells 34,501 shares via trusts - Stock Titan
Form 144 Maze Therapeutics For: 3 August By Investing.com - Investing.com Canada
MAZE Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEarnings Turnaround - vinanet.vn
MAZE PE Ratio & Valuation, Is MAZE Overvalued - Intellectia AI
Maze Therapeutics, Inc. (MAZE): Analyzing A 126% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Maze Therapeutics (MAZE) Slips 2.91% as Shares Hover Near Key Support at $25.48NAAIM Exposure - dars.gov.et
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ADAR1 Capital Management LLC Sells 129,437 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
TradingKey - TradingKey
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Spruce Street Capital LP Makes New $5.97 Million Investment in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. Revenue Breakdown – NASDAQ:MAZE - TradingView
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maze Therapeutics Inc (MAZE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Cash Flow - TradingKey
Maze Therapeutics Inc (MAZE) Balance Sheet - TradingKey
MAZE|Maze Therapeutics Inc|Price:27.680| - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):